Sector News

Novartis’ Sandoz to acquire Aspen Japan for $331m

November 13, 2019
Life sciences

Novartis subsidiary Sandoz has signed an agreement to buy Aspen Japan operations and related intellectual property from Aspen Global for an upfront payment of €300m ($331m) in cash.

The terms of the deal also include a partial consideration of approximately €100m, subject to supply conditions and licensing opportunities, following the closing of the acquisition.

Aspen Japan is a wholly owned unit of Aspen Global, part of Aspen Pharmacare. South Africa-based Aspen Group is the parent company of the Japanese entity.

The company’s portfolio in Japan consists of around 20 off-patent branded drugs, including anaesthetics, speciality and local brands.

For the fiscal year ending in 2019, the products yielded €130m in sales.

Sandoz expects the acquisition to support its footprint in Japan, considered as the third-largest market for generics globally. The deal will complement the company’s hospital generic and biosimilar products.

Sandoz CEO Richard Saynor said: “The acquisition of Aspen’s Japanese operations would significantly strengthen our position in this country, a stable but growing generics market.

“We are committed to helping address patient and customer needs in the market as we aspire to become the world’s leading and most valued generics company.”

For Aspen, the divestiture is meant to enable better focus on its core pharmaceutical business.

Aspen Group chief executive Stephen Saad said: “Although our Japanese-based operations do not provide appropriate scale and leverage in relation to this focus, the strong management team, dedicated staff, speciality portfolio and the commercial platform represent an excellent opportunity for Sandoz when combined with their Japanese portfolio and product pipeline.”

Furthermore, Aspen Global signed a five-year manufacturing and supply agreement with Sandoz to supply active pharmaceutical ingredients, semi-finished and finished products for drugs covered under the deal.

This agreement will be effective from the completion of the transaction, expected in the first half of next year.

Source: Pharmaceutical Technology

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.